24-week Results from the Randomized Phase 2 Dose Expansion Stage of the PRISM Trial Evaluating 4D-150 in High Need nAMD Patients: Injection-free Patient Analyses

CFTR Transgene Expression in Airway Epithelial Cells Following Aerosolized Administration of the AAV-based Gene Therapy 4D-710 to Adults with Cystic Fibrosis Lung Disease

Interim Results from the PRISM Randomized Phase 2 Dose Expansion Trial Evaluating 4D-150 in High Anti-VEGF Need Individuals with Neovascular (Wet) Age-Related Macular Degeneration

Phase 1/2 Clinical Trial Evaluating 4D-310 in Adults with Fabry Disease Cardiomyopathy: Interim Analysis of Cardiac and Safety Outcomes in Patients with 12–33 Months of Follow-up

First Interim Results (24 weeks) for the Randomized Phase 2 Dose Expansion Stage of the PRISM Clinical Trial of 4D-150 in High Need Patients with nAMD

Interim Results of the Phase 1/2 PRISM Trial Evaluating 4D-150, a Dual-Transgene Intravitreal Genetic Medicine for Neovascular (Wet) Age-Related Macular Degeneration